Medicus Pharma Seeks FDA Priority Voucher for SkinJect's Non-Invasive BCC Therapy

Medicus Pharma has submitted a FDA priority voucher application for its partner SkinJect's non-invasive BCC therapy, Doxorubicin Microneedle Array. The application seeks expedited regulatory review, potentially reducing review timelines to 1-2 months. The FDA intends to award only a limited number of vouchers, and Medicus Pharma believes SkinJect is well-positioned for inclusion. The therapy offers a localized, cost-effective alternative to current BCC treatments and addresses a significant public health burden.